NCT02914262View on ClinicalTrials.gov

Single Ascending Dose Study to Assess the Safety, Tolerability, PK and PD Effects in Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

November 30, 2016

Study Completion Date

January 31, 2017

Conditions
IBD
Interventions
DRUG

AKB-4924

Comparison of different dosages of AKB-4924

OTHER

Placebo

Placebo comparator

Trial Locations (1)

Unknown

INC Research, Toronto

Sponsors
All Listed Sponsors
lead

Aerpio Therapeutics

INDUSTRY

NCT02914262 - Single Ascending Dose Study to Assess the Safety, Tolerability, PK and PD Effects in Male Volunteers | Biotech Hunter | Biotech Hunter